JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Recursion Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

6.48 3.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.37

Max

6.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-24M

-202M

Pardavimai

10M

15M

Pelno marža

-1,373.259

Darbuotojai

800

EBITDA

-26M

-191M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-3.7% downside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

458M

2.8B

Ankstesnė atidarymo kaina

2.97

Ankstesnė uždarymo kaina

6.48

Naujienos nuotaikos

By Acuity

67%

33%

327 / 375 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-25 17:53; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

2025-07-25 15:58; UTC

Uždarbis
Pagrindinės rinkos jėgos

Aon Shares Rise After 2Q Earnings Beat

2025-07-25 15:08; UTC

Pagrindinės rinkos jėgos

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

2025-07-25 21:40; UTC

Rinkos pokalbiai

Starbucks' Spending Hikes Are Misdirected -- Market Talk

2025-07-25 21:23; UTC

Rinkos pokalbiai

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

2025-07-25 20:40; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 20:10; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 19:56; UTC

Uždarbis

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

2025-07-25 19:14; UTC

Rinkos pokalbiai

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

2025-07-25 19:10; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

2025-07-25 19:01; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 18:45; UTC

Rinkos pokalbiai

Gold Ends Down Week on Lower Note -- Market Talk

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Sale Could Fetch Around $1B, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH in Talks to Sell Marc Jacobs -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

2025-07-25 17:38; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

2025-07-25 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Extends Decline -- Market Talk

2025-07-25 17:13; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 16:46; UTC

Uždarbis

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

2025-07-25 16:45; UTC

Uždarbis

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

2025-07-25 16:27; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-25 16:02; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

2025-07-25 15:34; UTC

Uždarbis

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

2025-07-25 15:06; UTC

Rinkos pokalbiai

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

2025-07-25 15:05; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

2025-07-25 14:45; UTC

Rinkos pokalbiai

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

2025-07-25 14:44; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

2025-07-25 14:36; UTC

Rinkos pokalbiai
Uždarbis

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Akcijų palyginimas

Kainos pokytis

Recursion Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-3.7% į apačią

12 mėnesių prognozė

Vidutinis 6.25 USD  -3.7%

Aukščiausias 8 USD

Žemiausias 4 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Recursion Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.15 / 4.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

327 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.